Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Trial Profile

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Acronyms SEMAPHORE
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.
    • 15 Feb 2017 Planned primary completion date changed from 1 Dec 2019 to 15 Sep 2020.
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top